Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

Louisiana State University Health Sciences Center Shreveport

Status and phase: Completed; Early Phase 1

Conditions: Vitamin D Deficiency

Treatments: Drug: Vitamin D + L-cysteine; Drug: Vitamin D; Drug: Placebo; Drug: L-cysteine

Study type: Interventional

Funder types: Other

Identifiers

NCT04939792

HRP-503

Details and patient eligibility

About

Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials have shown that, while supraphysiological high doses of VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them. Recent studies have also questioned the therapeutic effects of high-dose VD supplementation. Severe VD deficiency has been associated independently with the future risk of mild cognitive impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews conclude that excess oxidative stress is one of the major risk factors for AD and support a potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD) supplementation in the treatment of Alzheimer disease symptoms. This application presents the investigators' design for a randomized, double-blind, placebo-controlled clinical trial to test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more successful at optimizing the statuses of 25(OH)VD [biological signatures] and simultaneously decreasing TNF-α, IR [functional or clinical outcomes], and oxidative stress, suggesting a better therapeutic approach compared with supplementation with VD alone in AA subjects.

Enrollment: 165 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• African American volunteers only
• Participants between the ages of 18 and 65
• Must be In good general health
• Women with negative pregnancy tests

Exclusion criteria

• Subjects with Diabetes, Heart disease, Sickle Cell disease, or Epilepsy
• Subjects with serum positive pregnancy test or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

165 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo. During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle

Treatment:

Drug: Placebo

L-Cysteine

Experimental group

Description:

LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle

Treatment:

Drug: L-cysteine

Vitamin D3

Experimental group

Description:

VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle

Treatment:

Drug: Vitamin D

Vitamin D3 and L-Cysteine

Experimental group

Description:

VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle

Treatment:

Drug: Vitamin D + L-cysteine